Nonlinear kinetics and pharmacologic response to mibefradil

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 249-257

  Du Souich, Patrick ^a,b   Besner, Jean Guy ^a,b   Clozel, Jean Paul ^a,b   Welker, Horst A ^a,b   Lefebvre, Marc ^a,b   Caillé, Gilles ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MIBEFRADIL;

ADULT; ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034064941     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104616     Document Type: Article

References (35)

1. 2+-channels by RO 40-5967. Circ Res 1994;75:144-8.
2. 2+ in dog coronary arterial vascular muscle cells by RO 40-5967. J Cardiovasc Pharmacol 1994;24:1-7.
3. 3. Clozel JP, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989:14:713-21.
4. 4. Brogden RN, Markham A. Mibefradil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. Drugs 1997;54:774-93.
5. 5. Clozel JP, Osterreider W, Kleinbloesem CH, Welker HA, Schlappi B, Tudor R, et al. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;29:692-6.
6. 6. Welker HA, Eggers H, Kleinbloesem C, Erb K, Breithaup K, Butzer R, et al. Ro 40-5967: pharmacokinetics of a new calcium antagonist [abstract]. Eur J Clin Pharmacol 1989;36:A304.
7. 7. Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 1998;35:405-23.
8. 8. Abernethy DR. Pharmacologic and pharmacokinetic profile of mibefradil, T-and L-type calcium channel antagonist. Am J Cardiol 1997;80:4C-11C.
9. 9. Bernink PJLM, Prager G, Schelling A. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996;27:426-32.
10. 10. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992; 52:314-23.
11. 11. Wiltshire HR, Sutton BM, Keeps G, Betty AM, Angus DW, Madigan MJ, et al. Metabolism of the calcium antagonist mibefradil (POSICOR, Ro 40-5967); part II: metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man. Xenobiotica 1997;27:539-56.
12. 12. Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, et al. Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967); part III: comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 1997;27:557-71.
13. 13. Vargas Loza AM, Montes de Oca EI, Posadas de Rio FA. Sex differences in the enzymatic hydrolysis of acetylsalicylic acid by microsomes from various rat tissues. J Appl Toxicol 1997;17:347-51.
14. 14. Takahashi K, Tamagawa S, Sakano H, Katagi T, Mizuno N. Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Biol Pharmacol Bull 1995;18:1401-4.
15. 15. Cook CS, Karabatsos PJ, Schoenhard GL, Karim A. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharmacol Res 1995;12:1158-64.
16. 16. Buchthal J, Grund KE, Buchmann A, Schrenk D, Beaune P, Bock KW. Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur J Clin Pharmacol 1995;47:431-5.
17. 17. McKinnon RA, Burgess WM, Hall PM, Roberts-Thompson SJ, Gonzalez FJ, McManus ME. Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995;36:259-67.
18. 18. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60.
19. 19. Skerjanec A, Tawfik S, Tam YK. Nonlinear pharmacokinetics of mibefradil in the dog. J Pharmacol Sci 1996;85:189-92.
20. 20. Skerjanec A, Tawfik S, Tam YK. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs. J Pharmacol Exp Ther 1996;278:817-25.
21. 21. Bast A, Valk AJ, Timmerman H. Cytochrome P-450 metabolic-intermediate complex formation with a series of diphenhydramine analogs. Agents Action 1990;30:161-5.
22. 22. Bast A, Savenjie-Chapel EM, Noordhoek J. Relationship between molecular structure and cytochrome P450-metabolite intermediate complex formation, studied with orphenadrine analogues. J Pharm Sci 1984;73:953-6.
23. 23. Saville BA, Gray MR, Tam YK. Evidence for lidocaine-induced enzyme inactivation. J Pharm Sci 1989;78:1003-8.
24. 24. Hussain MD, Tam YK, Gray MR, Coutts RT. Mechanisms of time-dependent kinetics of diltiazem in the isolated perfused rat liver. Drug Metab Dispos 1994;22:36-42.
25. 25. Schwartz JB, Abernethy DR, Taylor AA, Mitchell JR. An investigation of the cause of accumulation of verapamil during regular dosing in patients. Br J Clin Pharmacol 1985;19:512-6.
26. 26. Abernethy DR, Montamat SC. Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. Am J Cardiol 1987;60:1161-201.
27. 27. Montamat SC, Abernethy DR. N-Monodemethyldiltiazem is the predominant metabolite of diltiazem. Br J Clin Pharmacol 1987;24:185-9.
28. 28. Klotz U, Antonin KH, Bieck PR. Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol 1976;10:121-6.
29. 29. Klotz U, Reimann I. Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam. Eur J Clin Pharmacol 1981;21:161-3.
30. 30. Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, et al. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999;47:291-8.
31. 31. Welker H. Single-and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects. J Pharm Pharmacol 1998;50:983-7.
32. 32. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27:173-9.
33. 1-receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997;98:273-92.
34. 34. Welker HA, Banken L. Mibefradil pharmacokinetic and pharmacodynamic population analysis. Int J Clin Pharm Res 1998;18:63-71.
35. 35. Petrie JR, Glen SK, MacMahon M, Crome R, Meredith PA, Elliott HL, et al. Haemodynamic, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. J Hypertens 1995;13:1842-6.